AMD-3100 AnorMED

IDrugs

Volumn 3, Issue 7, 2000, Pages 811-816

  Vartanian, Jean Pierre ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0011881449     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Potent inhibitor of human immunodeficiency virus (HIV) replication by aromatic linked bis-azamacrocyles: Synthesis and effects of macrocyclic ring size. Padmanabhan S, Bridger G, Skerij R et al INT CONF ANTIVIRAL RES 1994 Abs 30
2. Potent inhibitor of human immunodeficiency virus (HIV) replication by aromatic linked bis-azamazcrocycles: Synthesis and effects of substitution at the aromatic linker. Skerij R, Bridger G, Padmanabban S et al INT CONF ANTIVIRAL RES 1994 Abs 31
3. Potent inhibition of human immunodeficiency virus (HIV) replication by aromatic linked bis-azamacrocycles: Structure-activity relationships. Bridger G, Skerij R, Padmanabhan S et al INT CONF ANTIVIRAL RES 1994 Abs 32
4. Structure-activity relationships in the anti-HIV activity of bis-azamacrocycles: Highly potent inhibitors of HIV replication with a unique mechanism of action. Bridger GJ, Skerij RT, Padmanabhan S, Thornton D, Henson GW, Abrams MJ, Yamamoto N, DeVreese K, Pauwels R, DeClercq E ACS 1994 207 MEDI-23
5. Synthesis and anti-HIV activity of aromatic linked bis-azamacrocycles. Skerij RT, Bridger GJ, Padmanabhan S, Thornton D, Henson GW, Abrams MJ, Yamamoto N, DeVreese K, Pauwels R, DeClercq E ACS 1994 207 MEDI-24
6. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative. DeClercq E, Yamamoto N, Pauwels R1 Balzarini J, Witvrouw M, DeVreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R, Thornton D ANTIMICROB AGENTS CHEMOTHER 1994 38 4 668-674
7. SDZ SID 791 (JM 3100): A mechanistically unique anti-HIV agent with potent antiviral activity in vitro and in vivo. Datema R, Abrams M, Bridger G, DeClercq E, DeVreese K, Hauck C, Henson G, McCune M, Rabin L, Rosenwirth B, Schweitzer A, Seifert J, Witvrouw M ICAAC 1994 34 Abs F158
8. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. Bridger GJ, Skerij RT, Thornton D, Martellucci SA, Henson GW, Abrams MJ, Yamamoto N, DeVreese K, Pauwels R, DeClercq E J MED CHEM 1995 38 2 366-378
9. Resistance development to the bicyclam SID-791, a potent inhibitor of HIV-1 and HIV-2. Este JA, DeVreese K, Witvrouw M, DeClercq E CAN J INFECT DIS 1995 6 Suppl C Abs 0644
10. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams. Bridger GJ, Skerij RT, Padmanabhan S, Martellucci SA, Henson GW, Abrams MJ, Joao HC, Witvrouw M, DeVreese K, Pauwels R, DeClercq E J MED CHEM 1996 39 1 109-119
11. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Datema R, Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Rosenwirth B, Seifert J, McCune JM ANTIMICROB AGENTS CHEMOTHER 1996 40 3 750-754
12. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Este JA, DeVreese K, Witvrouw M, Schmit J C, Vandamme A M, Anne J, Desmyter J, Henson GW, Bridger G, De Clercq E ANTIVIRAL RES 1996 29 2-3 297-307
13. Trends in Drug Research - 11th Noorwijkerhout-Camerino Symposium, Noordwijkerhout, The Netherlands. Garrat J IDDB MEETING REPORT 1997 May 11-15
14. Chemokines: Latest Advances in Understanding and Therapeutic Development, IBC's Fourth Annual Industry Symposium, Baltimore, MD, USA. Newton RC IDDB MEETING REPORT 1997 June 5-6
15. Inhibition of HIV-1 replication by the bicyclam AMD-3100 a CXCR4 antagonist. Schols D, Cabrera C, Henson G et al ICAAC 1997 37 Abs I66
16. Low molecular weight chemokine inhibitors for blocking HIV infection disclosed. EMERGING PHARMACEUTICALS 1997 6 122-3
17. Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS. Ponath P EXP OPIN INVEST DRUGS 1998 7 1 1-18
18. HIV co-receptors - target for the next generation of antivirals? SCRIP 1998 2301 19
19. CXCR4 is the target for the potent anti-HIV activity of bicyclams. Schols D, Struyf S, Wuyts A, Van Damme J, Bridger GJ, Henson GW, DeClercq E INT CONF ANTIVIRAL RES 1998 Abs 28
20. Antiviral Research - 11th International Conference (Part II), San Diego, CA, USA. Field KA IDDB MEETING REPORT 1998 April 5-10
21. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. DeVreese K, VanNerum I, Vermeire K, Anne J, DeClercq E ANTIMICROB AGENTS CHEMOTHER 1997 41 12 2616-2620
22. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. De Vreese K, Reymen D, Griffin P, Steinkasserer A, Werner G, Bridger GJ, Este J, James W, Henson GW, Desmyter J, Anne J, De Clercq E ANTIVIRAL RES 1996 29 2-3 209-219
23. Open house presentation - AnorMED Inc. ANN BIOPARTNERING EUROPE MEET 1998 October 26-27
24. Chemokines in Infection and Inflammatory Disease - The Royal Society of Medicine, London, UK. Zheng R IDDB MEETING REPORT 1999 January 11
25. New bicyclam-AZT conjugates: design, synthesis anti-HIV evaluation and their interaction with CXCR-4 coreceptor. Dessolin J, Galea P, Vlieghe P, Chermann JC, Kraus JL J MED CHEM 1999 42 2 229-241
26. T-134, a small molecule CXCR4 inhibitor, has no cross-drug resistance with AMD-3100, a CXCR4 antagonist with a different structure. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N, Nakashima H J VIROL 1999 73 2 1719-1723
27. A low-molecular weight inhibitor against the chemokine receptor CXCR4: Strong anti-HIV peptide T140. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaska A, Ibuka T, Yamamoto N, Nakashima H, Fujii N BIOCHEM BIOPHYS RES COMMUN 1998 253 3 877-882
28. News from ISAR Jerusalem, Israel. Contrafouris Y IDDB MEETING REPORT 1999 March 22
29. Blockade of CXCR4 prevents the emergence of X4, T-cell tropic, syncytium-inducing strains of HIV-1. Este JA, Cabrera C, Gutierrez A, Blanco J, Schols D, Clotet B, Henson G, Bridger G, DeClercq E ANTIVIRAL RES 1999 41 2 Abs 4
30. International Society for Antiviral Research - 12th International Conference (Part V), Retrovirus Infections, Jerusalem, Israel. IDDB MEETING REPORT 1999 March 21-25
31. International Society for Antiviral Research - 12th International Conference (Part VIII), Jerusalem, Israel. IDDB MEETING REPORT 1999 March 21-25
32. AnorMED Inc begins phase II trial for AIDS drug. AnorMED Inc PRESS RELEASE 1999 May 27
33. AnorMED announces 4th quarter & 1999 year-end results profitable operations, licensing agreement and IPO highlight fiscal 1999. AnorMED Inc PRESS RELEASE 1999 June 3
34. New targets for the chemotherapy of HIV infections. De Clercq E J ANTIMICROB CHEMOTHER 1999 44 Suppl A Abs 08-37
35. AnorMED Products - AMD-3100: A small molecule anti-HIV fusion inhibitor. AnorMED Inc COMPANY WORLD WIDE WEB SITE 1999 July 27
36. Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors. Kilby JM EXP OPIN INVEST DRUGS 1999 8 8 1157-1170
37. Virology - 11th International Congress, Sydney, Australia. IDDB MEETING REPORT 1999 August 7-13
38. AnorMED announces first quarter results. AnorMED Inc PRESS RELEASE 1999 August 23
39. AnorMED products. AnorMED Inc COMPANY WORLD WIDE WEB SITE 1999 August 24
40. Product portfolio - 1999. AnorMED Inc COMPANY BROCHURE 1999 September 22
41. Corporate profile. AnorMED Inc COMPANY BROCHURE 1999 September 22
42. AnorMED Inc raises $30.5 million in initial public offering, shares listed for trading on Toronto Stock Exchange. AnorMED Inc PRESS RELEASE 1999 March 5
43. First Quarter Report - AnorMED. AnorMED Inc 1ST QUARTER REPORT 1999 June 30
44. The CXCR4 receptor antagonist, AMD3100, strongly inhibits HIV infection in SCID-hu PBMC mice. Schols D, Fonteyn E, Bridger G, Henson G, DeClercq E ICAAC 1999 39 Abs 915
45. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. Bridger GJ, Skerlj RT, Padmanabhan S, Martellucci SA, Henson GW, Struyf S, Witvrouw M, Schols D, DeClercq E J MED CHEM 1999 42 19 3971-3981
46. BioPartnering - AnorMED Inc. ANN BIOPARTNERING EUROPE MEET 1999 October 18-19
47. Annual Report 1999 - AnorMED Inc. AnorMED Inc ANNUAL REPORT 1999 March 31
48. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, Minoguchi S, Tamamura H, Waki M, Matsumoto A, Fujii N, Shida H, Hoxie JA, Peiper SC, Yamamoto N J VIROL 1999 73 9 7489-7496
49. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. Egberink HF, DeClercq E, VanVlietal W, Balzarini J, Bridger GJ, Henson G, Horzinek MC, Schols D J VIROL 1999 73 8 6346-6352
50. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, Clotet B, Schols D, DeClercq E J VIROL 1999 73 7 5577-5585
51. Shared usage of the chemokine receptor CXCR4 by primary and laboratory- adapted strains of feline immunodeficiency virus. Richardson J, Pancino G, Merat R, Leste-Lasserre T, Moraillon A, Schneider-Mergener J, Alizon M, Sonigo P, Heveker N J VIROL 1999 73 5 3661-3671
52. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. DeClercq E EUR CYTOKINE NETW 1999 10 2 281-285
53. The role of chemokine receptors in HIV infection. Rowland-Jones S SEXUALLY TRANSMITTED INFECTIONS 1999 75 3 148-151
54. Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. VanGelder J, Witvrouw M, Pannecouque C, Henson G, Bridger G, Naesens L, DeClercq E, Annaert P, Shafiee M, VanDenmooter G, Kinget R, Augustijns P INT J PHARM 1999 186 2 127-136
55. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Este JA, Cabrera C, DeClercq E, Struyf S, Van Damme J, Bridger G, Skerlj RT, Abrams MJ, Henson G, Gutierrez A, Clotet B, Schols D MOL PHARMACOL 1999 55 1 67-73
56. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. Li JJ, Low JE, Showalter HDH CHEMTRACTS 1999 12 57-60
57. The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells. Schols D, DeClercq E J GEN VIROL 1998 79 9 2203-2205
58. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, DeClercq E, Moore JP NAT MED 1998 4 1 72-77
59. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. Schols D, Struyf S, Van Damme J, Este JA, Henson G, DeClercq E J EXP MED 1997 186 8 1383-1388
60. AnorMED completes $21 million bought deal financing. AnorMED Inc PRESS RELEASE 2000 February 11
61. Retroviruses and Opportunistic Infections - Seventh Conference, San Francisco, CA, USA. IDDB MEETING REPORT 2000 January 30-February 2
62. Antiretroviral therapy: State of the HAART. Vella S, Palmisano L ANTIVIRAL RES 2000 45 1 1-7
63. Synthesis and structure-activity relationships of bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. Skerlj R, Bridger G, Pabmanabhan S, Martellucci S, Henson G, Struyf S, Witvrouw M, Schols D, DeClercq E ACS 2000 219 MEDI-122
64. Microbicides 2000, Basic Science, Animal Models and In Vitro Assays, Washington DC, USA. Coombs RW IDDB MEETING REPORT 2000 March 13-16
65. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Schols D, Este JA, Henson G, DeClercq E ANTIVIRAL RES 1997 35 3147-156
66. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD-3100. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, DeClercq E, Alizon M J VIROL 1998 72 8 6381-6388
67. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. DeVreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, Anne J, DeClercq E, Datema R, Werner G J VIROL 1996 70 689-696
68. American Chemical Society - 219th National Meeting (Part XVIII), San Francisco, CA, USA. IDDB MEETING REPORT 2000 March 26-30
69. Current antiviral agents FactFile: 1999-2000 update. 5th Edition: Part II - Human immunodeficiency viruses. Kinchington D, Gee S, Balzarini J, Gait M, DeClercq E, Field HJ INT ANTIVIRAL NEWS 2000 8 1 4-21
70. CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entry into CD4(+) T cells. Zhang Y, Hatse S, DeClercq E, Schols D J VIROL 2000 74 4 2011-2016
71. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Blanco J, Barretina J, Henson G, Bridger G, DeClercq E, Clotet B, Este JA ANTIMICROB AGENTS CHEMOTHER 2000 44 1 51-56
72. Chemokine receptor antagonists. Horuk R, Ng HP MED RES REV 2000 20 2 155-168
73. Differential signalling of the chemokine receptor CXCR4 by stromal cell-derived factor 1 and the HIV glycoprotein in rat neurons and astrocytes. Lazarini F, Casanova P, Tham TN, DeClercq E, Arenzana-Seisdedos F, Baleux F, Dubois-Dalcq M EUR J NEUROSCI 2000 12 1 117-125
74. AIDS researchers explore new drug options. Stephenson J J AM MED ASSOC 2000 283 9 1125
75. Summary of the American Chemical Society 219th National Meeting San Francisco, CA, USA Gray D, McKinnon C IDDB MEETING REPORT 2000 March 26-30
76. Current antiviral agents factfile: 1999-2000 update. INT ANTIVIRAL NEWS 2000 8 1
77. Quaternary ammonium salts inhibiting HIV replication in vitro. Pannecouque C, Fikkert V, Schols D, De Clerq E, Witvrouw M INT CONF ANTIVIRAL RES 2000 April 16-21 Abs 23
78. Pharmacodynamics of leukocytosis after AMD-3100, a novel CXCR-4 chemokine receptor antagonist. Hendrix CW, Flexner CW, McFarland RT, Shah NS, Fuchs EJ, Henson GW CLIN PHARMACOL THER 2000 67 2 PIII-62
79. Summary of the 13th International Conference on Antiviral Research, Baltimore, MD, USA. Grierson K IDDB MEETING REPORT 2000 April 16-21
80. AnorMED Inc. CIBC World Markets ANALYST REPORT 2000 January 18